UroAlert - GU Oncology Daily

July 29, 2026

Videos

Peer-to-Peer Clinical Conversations

PSMAddition Trial of ADT, ARPI, and Lutetium-177 in Metastatic Hormone-Sensitive Prostate Cancer - Fred Saad

Fred Saad

Fred Saad presents a PSMAddition subgroup analysis examining rPFS benefit by disease volume and timing in the trial of ADT plus any ARPI with or without lutetium-177 in metastatic hormone-sensitive prostate cancer.

View

Real-World Claims Analysis of Blue-Light Cystoscopy in NMIBC – Mark Tyson

Mark Tyson

Mark Tyson reviews a real-world cost analysis of blue-light versus white-light cystoscopy.

View

Beyond the Abstracts

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications - Beyond the Abstract

Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis - Beyond the Abstract

Conference Coverage

ASCO 2026: Phase II Study of Frontline Gemcitabine, 5-Flurouracil/leucovorin, and Cisplatin in Advanced Urachal and Non-Urachal Urinary Tract Adenocarcinoma

ASCO 2026: Discussant - Is the Best yet to Come in Kidney Cancer?

AUA 2026: Cost Effectiveness Analysis of Sasanlimab + BCG for High-Risk NMIBC: Analysis From CREST

SES AUA 2026: Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist  

EAU 2026: State of the Art Lecture: Why Are Germline and Somatic Alterations in Prostate Cancer Important?

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Testicular Cancer

Login